Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.
Bristol Myers Squibb (NYSE: BMY) generates frequent news across drug development, regulatory milestones, clinical data and corporate actions, reflecting its role as a global biopharmaceutical company focused on serious diseases. News coverage on this page centers on how the company’s cardiovascular, oncology, hematology, immunology and neuroscience programs progress from clinical trials to regulatory decisions and real-world use.
Recent updates have highlighted positive Phase 3 trial results for Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy in the SCOUT-HCM study, including statistically significant improvements in left ventricular outflow tract gradients and safety findings consistent with adult experience. Other headlines feature regulatory developments such as the U.S. Food and Drug Administration granting priority review to an Opdivo (nivolumab) plus chemotherapy combination for previously untreated advanced classical Hodgkin lymphoma, and the FDA’s approval of Breyanzi (lisocabtagene maraleucel; liso-cel) for adults with relapsed or refractory marginal zone lymphoma.
Investors and followers of BMY can also expect news on hematology research presented at major medical meetings, including data on investigational targeted protein degradation agents like golcadomide and BMS-986458, and long-term follow-up results for Breyanzi in large B-cell and follicular lymphomas. Corporate and financial items appear as well, such as dividend declarations, debt offerings, tender offers for outstanding notes, and presentations at healthcare investment conferences.
This news feed brings together company press releases, clinical trial readouts, regulatory updates, access and affordability agreements, and SEC-reported events. For users tracking BMY stock, it offers a single place to review how Bristol Myers Squibb’s pipeline, marketed products and capital markets activity evolve over time. Bookmark this page to quickly review new trial results, FDA decisions, access initiatives and financial disclosures related to Bristol Myers Squibb.
BioAtla (Nasdaq: BCAB) announced a clinical collaboration with Bristol Myers Squibb (NYSE: BMY) to explore its lead candidates, BA3011 and BA3021, in combination with Opdivo (nivolumab) for solid tumors. BioAtla will sponsor the trials and bear execution costs, while Bristol Myers Squibb will supply Opdivo. Both candidates target AXL and ROR2, which are significant in various cancers, especially after prior anti-PD-1 therapy. This collaboration aims to enhance treatment options for patients with unmet medical needs.
Bristol Myers Squibb (NYSE:BMY) has expanded its collaboration with Arsenal Biosciences to develop next-generation T cell therapies for solid tumors. This follows an option exercise from their December 2020 agreement, which includes undisclosed financial milestone payments. Bristol Myers Squibb will be responsible for the development and commercialization of the new preclinical candidates. The collaboration highlights the potential of ArsenalBio's programmable cell therapy technology, aiming to improve patient outcomes in cancer treatment.
Pyramid Biosciences has appointed Dr. Brian Lestini as the new Chief Executive Officer, succeeding co-founder Dr. Kollol Pal, who remains as Chief Scientific Officer. Dr. Lestini joined the company in March 2021 and has extensive experience in oncology, notably at Bristol-Myers Squibb (NYSE: BMY). The company continues to focus on its clinical-stage pipeline, particularly the lead program PBI-200, a TRK inhibitor targeting brain cancers. This leadership change aims to further enhance the company’s growth and development of precision oncology therapies.
Century Therapeutics (NASDAQ: IPSC) and Bristol Myers Squibb (NYSE: BMY) have announced a collaboration to develop allogeneic cell therapies targeting hematologic malignancies and solid tumors. Century will receive
Bristol Myers Squibb (NYSE:BMY) highlighted its growth strategy during the J.P. Morgan Healthcare Conference. The company announced a $5 billion share repurchase plan for Q1 2022, alongside guidance for 2022 total revenues of approximately $47 billion. Key drivers for growth include a diverse product portfolio expected to generate $10-$13 billion in revenue by 2025, promising mid- to late-stage assets, and a robust early-stage pipeline. Additionally, BMY reaffirmed its long-term financial targets, emphasizing strong cash flows of $45-$50 billion from 2022 to 2024.
Bristol Myers Squibb (BMY) has expanded its partnership with ZS, a professional services firm, to enhance its worldwide commercial analytics capabilities. This agreement builds on a successful collaboration initiated in 2015, focusing on BMS’s Business Insights & Analytics group. The partnership aims to utilize data science, marketing mix strategies, forecasting, and brand analytics across over 65 markets. ZS, with over 35 years of experience, is committed to helping BMS drive impactful decision-making to improve patient outcomes.
Bristol Myers Squibb (NYSE: BMY) will present at J.P. Morgan’s 40th Annual Virtual Healthcare Conference on January 10, 2022. The formal presentation by Giovanni Caforio, M.D., Board Chair and CEO, is scheduled for 7:30 a.m. ET. The event will be webcast live, with related materials available beforehand. A replay and archived version will be accessible after the event. Bristol Myers Squibb is committed to discovering and delivering innovative medicines for serious diseases.
Bristol Myers Squibb (NYSE:BMY) will announce its fourth quarter 2021 results on
Participants can access the live webcast at BMS.com or through dial-in options. A replay will be available three hours post-call until
Bristol Myers Squibb (NYSE:BMY) has announced that the U.S. Food and Drug Administration (FDA) has approved Orencia® (abatacept) for preventing acute graft versus host disease (aGvHD) in patients receiving hematopoietic stem cell transplants. This marks the fourth FDA indication for Orencia, which is already established in treating several rheumatic diseases. The approval is particularly significant given the higher risk of aGvHD in racial and ethnic minority populations due to challenges in finding matched donors.
Exelixis, Inc. has initiated the dose-escalation stage of the STELLAR-002 trial, exploring XL092, a next-generation tyrosine kinase inhibitor, in combination with immuno-oncology therapies for advanced cancers. Collaborating with Bristol-Myers Squibb and Nektar Therapeutics, the trial aims to assess safety and efficacy among patients with advanced solid tumors. The study will focus on renal cell carcinoma, urothelial carcinoma, and metastatic castration-resistant prostate cancer, with primary endpoints including objective response rates and progression-free survival.